We are live on ! Find out more
ATYR

aTyr Pharma
ATYR

39 hedge funds and large institutions have $87.6M invested in aTyr Pharma in 2017 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

267% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 3

130% more capital invested

Capital invested by funds: $38M → $87.6M (+$49.5M)

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

22% more funds holding

Funds holding: 32 → 39 (+7)

1.86% more ownership

Funds ownership: 3.34% → 5.2% (+1.9%)

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

Holders
39
Holders Change
+7
Holders Change %
+21.88%
% of All Funds
0.97%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
11
Increased
5
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
RG
Redmile Group
California
+$6.24M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$5.88M
3
EC
EcoR1 Capital
California
+$5.43M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$1.24M
5
AG
Artal Group
Luxembourg
+$827K

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$280K
2
Goldman Sachs
Goldman Sachs
New York
-$75K
3
BlackRock
BlackRock
New York
-$68.7K
4
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$21K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$18.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
$150K -$556 -12 -0.6%
Bank of New York Mellon
27
Bank of New York Mellon
New York
$137K – – –
SIM
28
Spark Investment Management
New York
$117K +$76.8K +1,657 New
QI
29
Quotient Investors
New York
$112K – – –
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$107K +$18.9K +407 +37%
Creative Planning
31
Creative Planning
Kansas
$86K – – –
Citigroup
32
Citigroup
New York
$37K -$1.67K -36 -6%
UBS Group
33
UBS Group
Switzerland
$32K +$20.9K +452 New
RE
34
RBC Europe
United Kingdom
$30.3K +$19.9K +429 New
JP Morgan Chase
35
JP Morgan Chase
New York
$9K +$5.98K +129 New
Parallax Volatility Advisers
36
Parallax Volatility Advisers
California
$7K – – –
Federated Hermes
37
Federated Hermes
Pennsylvania
$1K -$139 -3 -13%
Goldman Sachs
38
Goldman Sachs
New York
– -$75K -1,582 Closed
Acadian Asset Management
39
Acadian Asset Management
Massachusetts
– -$21K -452 Closed
Manulife (Manufacturers Life Insurance)
40
Manulife (Manufacturers Life Insurance)
Ontario, Canada
– -$3K -54 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– +$46 +1 New
1
2

ATYR Hedge Fund Activity: Q3 2017 in Review

39 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q3 2017, worth a combined $87.6M — up 130% from $38M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new ATYR positions and 3 closed out — a net gain of 8 holders — while 5 added to existing stakes and 8 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $6.24M. The largest seller was Alyeska Investment Group, cutting an estimated $280K.

  • 39 institutional investors held aTyr Pharma (ATYR) as of Q3 2017, up from 32 in Q2 2017.
  • Funds reported $87.6M of aTyr Pharma stock for Q3 2017, up 130% quarter-over-quarter.
  • 11 funds opened new aTyr Pharma positions in Q3 2017 and 3 closed out, a net change of +8 holders.
  • The largest aTyr Pharma buyer in Q3 2017 was Redmile Group, an estimated $6.24M added.
  • The largest aTyr Pharma seller in Q3 2017 was Alyeska Investment Group, an estimated $280K sold.

Based on aggregated 13F filings for Q3 2017.